Fructose and sucrose intake promotes de novo lipogenesis in the liver [91,92], and a recent pre-clinical study indicates that a fructokinase (also called ketohexokinase) inhibitor improves NAFLD/NASH [91]. This evidence concerns the gene KHK and metabolic dysfunction-associated steatohepatitis.